![](https://library.celltelligence.com/wp-content/uploads/2021/10/Gilead_Announcement.png)
$0
The EC Grants Yescarta Marketing Authorization in 2L LBCL
On Monday, October 17, Gilead (Kite) announced (press release) that the European Commission (EC) has granted Yescarta approval (CD19 CAR-T) for the treatment of DLBCL and high-grade B-cell lymphoma (HGBL) refractory patients or that have relapsed within 12 months of 1L chemoimmunotherapy (2L LBCL). Below, Celltelligence provides insights on Yescarta’s approval in the EU, while comparing it with key competitor Breyanzi (BMS’s CD19 CAR-T).